Propanc Biopharma Bags $100M Funds to Drive Digital Asset Plans

Propanc Biopharma, a Nasdaq-listed company, recently shared that it had secured a major financing deal worth up to $100 million to funnel into digital assets

This funding round was led by Hexstone Capital, a family office known for investing in major crypto assets, including Bitcoin (BTC). The deal signals a bold move for the biotech company as it looks to combine medical innovation with exposure to the fast-growing world of digital finance.

Fueling the Next Stage of Growth

According to the report, Hexstone Capital will give Propanc an initial $1 million investment under the new agreement. The firm may then offer up to $99 million in additional funding over the next year through a convertible preferred stock arrangement.

Like many crypto-focused companies, Propanc plans to use the funding raised to expand its digital asset portfolio. It will also use part of the funds to advance its lead cancer therapy, PRP, which is expected to enter first-in-human trials by 2026.

In a recent interview, Propanc’s CEO, James Nathanielsz, described the financing deal as a transformative phase. He said it would strengthen the company’s balance sheet while pushing forward its proenzyme-based cancer research program.

Although the company has not revealed which digital assets it plans to purchase, the move signals a growing trend among small-cap firms. Many are now choosing to hold cryptocurrencies as part of their financial foundation.

Biotech Firms Turn to Digital Assets as Funding Pressures Grow

Propanc’s move mirrors a broader trend sweeping through the biotech sector. In 2025, many small drug developers have started using digital assets and new funding models. They are doing this because traditional capital has become harder to access.

According to Jefferies healthcare analyst David Windley, the trend shows that biotech firms are trying to reignite investor interest. This comes after a long period of weak share prices and limited financing options.

Companies like ETHZilla (formerly 180 Sciences Corp.), Sonnet BioTherapeutics, and Sharps Technology have made similar moves. Their announcements often lead to brief stock surges as investors respond to the shift.

Propanc Shares Fall Amid Investor Caution

Despite the large financing announcement, Propanc’s stock fell 4% on Monday, dropping below $1. This extends a 43% decline over the past month, according to Yahoo Finance.

The market’s cautious response shows that investors are unsure. They are questioning whether combining biotech research with digital asset exposure will create lasting value

Many analysts view such moves as innovative but risky. This is particularly for early-stage biotech companies already managing long development timelines and high R&D costs

In June, VanEck’s Matthew Sigel called out small-caps firms over crypto investment claims. He said many have weak financial positions and extremely low market values. According to Sigel, these business strategies appear to be efforts to boost stock prices through misleading information.

The post Propanc Biopharma Bags $100M Funds to Drive Digital Asset Plans appeared first on TheCoinrise.com.